β-adrenoceptor modulation in chronic obstructive pulmonary disease: Present and future perspectives

Drugs

Volumn 73, Issue 15, 2013, Pages 1653-1663

  Matera, Maria Gabriella ^a   Calzetta, Luigino ^b   Cazzola, Mario ^c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN NATRIURETIC PEPTIDE; BRONCHODILATING AGENT; CORTICOSTEROID; FORMOTEROL; INDACATEROL; NADOLOL; PROPRANOLOL; SALMETEROL;

ACUTE HEART FAILURE; AEROSOL; AIRWAY OBSTRUCTION; ARTICLE; ARTIFICIAL VENTILATION; ASTHMA; AUTONOMIC DYSFUNCTION; BRONCHODILATATION; BRONCHOSPASM; CARDIOSELECTIVITY; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE CARDIOMYOPATHY; DISEASE SEVERITY; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; EXERCISE; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE VARIABILITY; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPOKALEMIA; LUNG FUNCTION; NONHUMAN; QT PROLONGATION; QUALITY OF LIFE; RESPIRATORY TRACT ALLERGY; SIDE EFFECT; SYMPATHETIC TONE; SYSTEMATIC REVIEW (TOPIC); TACHYCARDIA; VASODILATATION;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; CARDIOVASCULAR DISEASES; DRUG INVERSE AGONISM; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, ADRENERGIC, BETA;

EID: 84887250195     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0120-5     Document Type: Article

References (94)

1. Cazzola M, Calzetta L, Bettoncelli G, Cricelli C, Romeo F, Matera MG, Rogliani P. Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. Respir Med. 2012;106:249-56.
2. Cockcroft JR, Pedersen ME. β-blockade: benefits beyond blood pressure reduction? J Clin Hypertens (Greenwich). 2012;14:112-20.
3. Matera MG, Martuscelli E, Cazzola M. Pharmacological modulation of β-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. Pulm Pharmacol Ther. 2010;23:1-8.
4. 2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs. 2005;65:1595-610. (Pubitemid 41138983)
5. Cazzola M, Noschese P, D'Amato G, Matera MG. The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction. Chest. 2002;121:230-41. (Pubitemid 34114252)
6. van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of β-blockers in COPD: a concern for nonselective β-blockers. Chest. 2005;127:818-24. (Pubitemid 40775510)
7. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450-504.
8. 2-Agonist therapy in lung disease. Am J Respir Crit Care Med. 2013;187:690-6.
9. Billington CK, Hall IP. Novel cAMP signalling paradigms: therapeutic implications for airway disease. Br J Pharmacol. 2012;166:401-10.
10. Brueckner F, Piscitelli CL, Tsai CJ, Standfuss J, Deupi X, Schertler GF. Structure of β-adrenergic receptors. Methods Enzymol. 2013;520:117-51.
11. Johnson M. The β-adrenoceptor. Am J Respir Crit Care Med. 1998;158:S146-53.
12. Whalen EJ, Rajagopal S, Lefkowitz RJ. Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med. 2011;17:126-39.
13. Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ. Beta-arrestin: a protein that regulates beta-adrenergic receptor function. Science. 1990;248:1547-50.
14. Ahn S, Nelson CD, Garrison TR, Miller WE, Lefkowitz RJ. Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference. Proc Natl Acad Sci USA. 2003;100:1740-4. (Pubitemid 36254518)
15. Perry SJ, Baillie GS, Kohout TA, McPhee I, Magiera MM, Ang KL, Miller WE, McLean AJ, Conti M, Houslay MD, Lefkowitz RJ. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science. 2002;298:834-6. (Pubitemid 35231537)
16. Canning BJ. Reflex regulation of airway smooth muscle tone. J Appl Physiol. 2006;101:971-85. (Pubitemid 44352315)
17. van Gestel AJ, Kohler M, Clarenbach CF. Sympathetic overactivity and cardiovascular disease in patients with chronic obstructive pulmonary disease (COPD). Discov Med. 2012;14:359-68.
18. Andreas S, Anker SD, Scanlon PD, Somers VK. Neurohormonal activation as a link to systemic manifestations of chronic obstructive pulmonary disease. Chest. 2005;128:3618-24. (Pubitemid 41698701)
19. Volterrani M, Scalvini S, Mazzuero G. Decreased heart rate variability in patients with chronic obstructive pulmonary disease. Chest. 1994;106:1432-7. (Pubitemid 24346104)
20. Steward RI, Lewis M. Cardiac output during exercise in patients with COPD. Chest. 1986;89:199-205.
21. Patakas D, Louridas G, Kakavelas E. Reduced baroreceptor sensitivity in patients with chronic obstructive pulmonary disease. Thorax. 1982;37:292-5. (Pubitemid 12108482)
22. Heindl S, Lehnert M, Criée CP. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med. 2001;164:597-601. (Pubitemid 32801663)
23. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation. 2004;110:1308-12. (Pubitemid 39202350)
24. Poirier P, Lacasse Y, Marquis K, Jobin J, LeBlanc P. Post-exercise heart rate recovery and mortality in chronic obstructive pulmonary disease. Respir Med. 2005;99:877-86. (Pubitemid 40796563)
25. Jensen MT, Marott JL, Lange P, Vestbo J, Schnohr P, Nielsen OW, Jensen JS, Jensen GB. Resting heart rate is a predictor of mortality in COPD. Eur Respir J. 2013;42:341-9.
26. 1-receptor down-regulation in heart failure. Circ Res. 1986;59:297-309. (Pubitemid 17178124)
27. 2-adrenoceptors in the human heart: properties, function and alterations in chronic heart failure. Pharmacol Rev. 1991;43:203-42.
28. 2-adrenergic receptor density. J Cardiovasc Electrophysiol. 1996;7:1039-49. (Pubitemid 26389417)
29. 1-selective and nonselective β-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation. 1996;94:353-8. (Pubitemid 26266119)
30. 2 agonists and theophylline in stable chronic obstructive pulmonary disease. Thorax. 1999;54:730-6. (Pubitemid 29341411)
31. 2-agonists be considered an alternative first choice option for the treatment of stable COPD? Respir Med. 1999;93:227-9. (Pubitemid 29199600)
32. Cekici L, Valipour A, Kohansal R, Burghuber OC. Short-term effects of inhaled salbutamol on autonomic cardiovascular control in healthy subjects: a placebo-controlled study. Br J Clin Pharmacol. 2009;67:394-402.
33. Silke B, Hanratty CG, Riddell JG. Heart-rate variability effects of beta-adrenoceptor agonists (xamoterol, prenalterol, and salbutamol) assessed nonlinearly with scatterplots and sequence methods. J Cardiovasc Pharmacol. 1999;33:859-67. (Pubitemid 29242767)
34. Hanratty CG, Silke B, Riddell JG. Evaluation of the effect on heart rate variability of a beta2-adrenoceptor agonist and antagonist using non-linear scatterplot and sequence methods. Br J Clin Pharmacol. 1999;47:157-66. (Pubitemid 29078014)
35. 2-receptor agonist: a human in vivo study. Circulation. 1999;99:2402-7. (Pubitemid 29218235)
36. 2-adrenoceptor agonists: current and future direction. Br J Pharmacol. 2011;163:4-17.
37. Cazzola M, Imperatore F, Salzillo A, Di Perna F, Calderaro F, Imperatore A, Matera MG. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest. 1998;114:411-5. (Pubitemid 28387516)
38. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 2. Reassessment in the larger Quebec cohort. Chest. 2012;142:305-11.
39. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Crim C, Willits LR, Yates JC, Vestbo J. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65:719-25.
40. Hanania NA, Sharafkhaneh A, Barber R, Dickey BF. β-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med. 2002;165:1353-8. (Pubitemid 34522936)
41. Parker H, Brenya R, Zarich S, Manthous CA. β-agonists for patients with chronic obstructive pulmonary disease and heart disease? Am J Emerg Med. 2008;26:104-5. (Pubitemid 350235840)
42. Singer AJ, Emerman C, Char DM, Heywood JT, Kirk JD, Hollander JE, Summers R, Lee CC, Wynne J, Kellerman L, Peacock WF. Bronchodilator therapy in acute decompensated heart failure patients without a history of chronic obstructive pulmonary disease. Ann Emerg Med. 2008;51:25-34. (Pubitemid 350309450)
43. Minasian AG, van den Elshout FJ, Dekhuijzen PN, Vos PJ, Willems FF, van den Bergh PJ, Heijdra YF. Bronchodilator responsiveness in patients with chronic heart failure. Heart Lung. 2013;42:208-14.
44. Maak CA, Tabas JA, McClintock DE. Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure? J Emerg Med. 2011;40:135-45.
45. Coughlin SS, Metayer C, McCarthy EP, Mather FJ, Waldhorn RE, Gersh BJ, DuPraw S, Baughman KL. Respiratory illness, beta-agonists, and risk of idiopathic dilated cardiomyopathy: the Washington, DC, Dilated Cardiomyopathy Study. Am J Epidemiol. 1995;142:395-403.
46. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest. 2003;123:1964-9. (Pubitemid 36706719)
47. Hannink JD, van Helvoort HA, Dekhuijzen PN, Heijdra YF. Heart failure and COPD: partners in crime? Respirology. 2010;15:895-901.
48. Sengstock DM, Obeidat O, Pasnoori V, Mehra P, Sandberg KR, McCullough PA. Asthma, beta-agonists, and development of congestive heart failure: results of the ABCHF study. J Card Fail. 2002;8:232-8.
49. Bermingham M, O'Callaghan E, Dawkins I, Miwa S, Samsudin S, McDonald K, Ledwidge M. Are beta2-agonists responsible for increased mortality in heart failure? Eur J Heart Fail. 2011;13:885-91.
50. Campbell SC, Criner GJ, Levine BE, Simon SJ, Smith JS, Orevillo CJ, Ziehmer BA. Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2006;20:571-9.
51. Worth H, Chung KF, Felser JM, Hu H, Rueegg P. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011;105:571-9.
52. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C. Expert consensus document on β-adrenergic receptor blockers. Eur Heart J. 2004;25:1341-62. (Pubitemid 39004105)
53. 3 adrenoceptors. Br J Pharmacol. 2005;144:317-22. (Pubitemid 40313677)
54. Chang CL, Mills GD, McLachlan JD, Karalus NC, Hancox RJ. Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Intern Med J. 2010;40:193-200.
55. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91:v1-52.
56. National Clinical Guidelines Centre 2010. Chronic heart failure: national clinical guideline for diagnosis and management in primary care [online]. August 2010. http://www.nice.org.uk/nicemedia/live/13099/50514/50514.pdf. Accessed 16 May 2013.
57. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC, National Heart Lung and Blood Institute: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363-72. (Pubitemid 43947981)
58. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A. ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens. 2007;2007(25):1105-87. (Pubitemid 46924065)
59. Cazzola M, Matera MG. β-Blockers are safe in patients with chronic obstructive pulmonary disease, but only with caution. Am J Respir Crit Care Med. 2008;178:661-2.
60. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005; (19):CD003566.
61. Ni Y, Shi G, Wan H. Use of cardioselective β-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J Int Med Res. 2012;40:2051-65.
62. Loth DW, Brusselle GG, Lahousse L, Hofman A, Leufkens HG, Stricker BH. Beta-blockers and pulmonary function in the general population: the Rotterdam Study. Br J Clin Pharmacol. 2013. doi: 10.1111/bcp.12181.
63. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012;12:48.
64. Rutten F, Zuithoff N, Hak E, Grobbee D, Hoes A. β-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880-7.
65. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342:d2549.
66. Farland MZ, Peters CJ, Williams JD, Bielak KM, Heidel RE, Ray SM. β-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations. Ann Pharmacother. 2013;47:651-6.
67. Matera MG, Calzetta L, Rinaldi B, Cazzola M. Treatment of COPD: moving beyond the lungs. Curr Opin Pharmacol. 2012;12:315-22.
68. Cochrane B, Quinn S, Walters H, Young I. Investigating the adverse respiratory effects of beta-blocker treatment: six years of prospective longitudinal data in a cohort with cardiac disease. Intern Med J. 2012;42:786-93.
69. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of β blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008;63:301-5. (Pubitemid 351497940)
70. Suissa S, Ernst P. Biases in the observational study of beta blockers in COPD. Thorax. 2008;63:1026-7.
71. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between β-blocker therapy and outcomes in patients hospitalized with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax. 2012;67:977-84.
72. Mentz RJ, Wojdyla D, Fiuzat M, Chiswell K, Fonarow GC, O'Connor CM. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol. 2013;111:582-7.
73. Mentz RJ, Schulte PJ, Fleg JL, Fiuzat M, Kraus WE, Piña IL, Keteyian SJ, Kitzman DW, Whellan DJ, Ellis SJ, O'Connor CM. Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION). Am Heart J. 2013;165:193-9.
74. Rutten FH, Hoes AW. Chronic obstructive pulmonary disease: a slowly progressive cardiovascular disease masked by its pulmonary effects? Eur J Heart Fail. 2012;14:348-50.
75. 2-adrenoceptor and other signaling proteins produced by chronic administration of 'β-blockers' in a murine asthma model. Pulm Pharmacol Ther. 2008;21:115-24.
76. 2AR signaling in HEK293 cells. Naunyn Schmiedebergs Arch Pharmacol. 2011;383:209-16.
77. Paolillo S, Pellegrino R, Salvioni E, Contini M, Iorio A, Bovis F, Antonelli A, Torchio R, Gulotta C, Locatelli A, Agostoni P. Role of alveolar β2-adrenergic receptors on lung fluid clearance and exercise ventilation in healthy humans. PLoS One. 2013;8:e61877.
78. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche Z, Ho SB, Ehre C, Kesimer M, Knoll BJ, Tuvim MJ, Dickey BF, Bond RA. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol. 2008;38:256-62. (Pubitemid 351567693)
79. 2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci USA. 2009;106:2435-40.
80. Hanania NA, Singh S, El-Wali R, Flashner M, Franklin AE, Garner WJ, Dickey BF, Parra S, Ruoss S, Shardonofsky F, O'Connor BJ, Page C, Bond RA. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther. 2008;21:134-41.
81. Kazani S, Israel E. Treatment with β blockers in people with COPD. BMJ. 2011;342:d2655.
82. Page C. Paradoxical pharmacology: turning our pharmacological model upside down. Trends Pharmacol Sci. 2011;32:197-200.
83. Dickey BF, Walker JKL, Hanania NA, Bond RA. β-Adrenoceptor inverse agonists in asthma. Curr Opin Pharmacol. 2010;10:254-9.
84. Penn RB. Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma. Naunyn Schmiedebergs Arch Pharmacol. 2008;378:149-69.
85. Short PM, Williamson PA, Anderson WJ, Lipworth BJ. Randomized placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma. Am J Respir Crit Care Med. 2013;187:1308-14.
86. Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med. 2003;97:1014-20. (Pubitemid 37098766)
87. Tsagaraki V, Amfilochiou A, Markantonis SL. Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients. Int J Clin Pract. 2006;60:415-21.
88. Tashkin DP, Altose MD, Bleecker ER, Connett JE, Kanner RE, Lee WW, Wise R. The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. Am Rev Respir Dis. 1992;145:301-10.
89. van den Berge M, Vonk JM, Gosman M, Lapperre TS, Snoeck-Stroband JB, Sterk PJ, Kunz LI, Hiemstra PS, Timens W, Ten Hacken NH, Kerstjens HA, Postma DS. Clinical and inflammatory determinants of bronchial hyperresponsiveness in COPD. Eur Respir J. 2012;40:1098-105.
90. Irvin CG. Neutrophils, airway hyperresponsiveness and COPD: true, true and related? Eur Respir J. 2012;40:1067-9.
91. Zhu J, Qiu YS, Majumdar S, Gamble E, Matin D, Turato G, Fabbri LM, Barnes N, Saetta M, Jeffery PK. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med. 2001;164:109-16. (Pubitemid 33151307)
92. Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, Monteiro W, Berry M, Parker D, Wardlaw AJ, Pavord ID. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29:906-13. (Pubitemid 46711894)
93. Cohn L. Mucus in chronic airway diseases: sorting out the sticky details. J Clin Invest. 2006;116:306-8. (Pubitemid 43228347)
94. Au DH, Udris EM, Curtis JR, McDonell MB, Fihn SD. Association between chronic heart failure and inhaled β-2-adrenoceptor agonists. Am Heart J. 2004;148:915-20.